[Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKI in advanced non-small cell lung cancer patients with EGFR-TKI acquired resistance].
OBJECTIVE
To explore the therapeutic efficacy and safety of chemotherapy subsequent epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced non-small cell lung cancer (NSCLC) patients with EGFR-TKI acquired resistance.


METHODS
The clinical features of 36 advanced NSCLC patients with EGFR-TKI acquired resistance from Affiliated Zhongshan Hospital, Fudan University between May 2006 and April 2014 were retrospectively reviewed. Twenty-seven of them received chemotherapy subsequent EGFR-TKI and another 9 chemotherapy alone. The short-term response, progression-free survival and side effects of two groups were compared.


RESULTS
The objective response rates of chemotherapy subsequent EGFR-TKI and chemotherapy alone groups were 7.4% and 0 (P = 0.557), disease control rates 81.5% and 44.4% (P = 0.046) and median progression-free survival 3.3 and 2.5 months, respectively (P = 0.587). No significant differences existed in the rates of side effects between two groups (P > 0.05).


CONCLUSIONS
The disease control rates of chemotherapy subsequent EGFR-TKI group are higher than chemotherapy alone group, but there is no survival benefit. And the side effects of subsequent therapy are tolerable.
Department of Pulmonary Medicine, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiamin
J
Li
Department of Pulmonary Medicine, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China. Email: qyhong68@hotmail.com.
Qunying
Q
Hong
Department of Pulmonary Medicine, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xin
X
Zhang
Department of Pulmonary Medicine, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jie
J
Hu
Department of Pulmonary Medicine, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Chunxue
C
Bai
D000970:Antineoplastic Agents; D035843:Biomedical Research; D002289:Carcinoma, Non-Small-Cell Lung; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors; D006761:Hospitals; D006801:Humans; D008175:Lung Neoplasms; D047428:Protein Kinase Inhibitors; D012449:Safety
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors